Evaxion Biotech Q3 2024 GAAP EPS $(0.04) Beats $(0.31) Estimate, Sales $3.017M Beat $123.333K Estimate
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech reported a significant earnings beat for Q3 2024, with a GAAP EPS of $(0.04) compared to the estimated $(0.31), and sales of $3.017 million surpassing the expected $123.333 thousand.
October 31, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evaxion Biotech's Q3 2024 results significantly exceeded expectations, with a GAAP EPS of $(0.04) beating the $(0.31) estimate and sales of $3.017M surpassing the $123.333K estimate.
Evaxion Biotech's earnings and sales both significantly exceeded analyst expectations, which is likely to positively impact the stock price in the short term. The EPS beat by 87.1% and sales beat by 2.35K% indicate strong performance and potential investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100